Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PF-03622905
CAS:<p>PF-03622905: potent ATP-competitive PKC inhibitor, IC50: 5.6-74.1 nM for PKCα/βI/βII/γ/θ, high specificity for PKC.</p>Fórmula:C24H35N7O3Cor e Forma:SolidPeso molecular:469.59SRG-II-19F
<p>SRG-II-19F is a BRDT BD1 degrader, useful for studying ClpC2's impact on ClpC1P1P2 protease.</p>Fórmula:C80H109ClN16O14SCor e Forma:SolidPeso molecular:1586.34Aclantate
CAS:<p>Aclantate is a nonsteroidal anti-inflammatory drug.</p>Fórmula:C15H14ClNO4SPureza:98%Cor e Forma:SolidPeso molecular:339.79PROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Fórmula:C55H69N13O7SPureza:98%Cor e Forma:SolidPeso molecular:1056.28Biguanide
CAS:<p>Biguanide can reduce oxidative stress in rats with hyperglycemia.</p>Fórmula:C2H7N5Cor e Forma:SolidPeso molecular:101.11BRD3067
CAS:<p>BRD3067, a Tubacin derivative, inhibits HDAC6 (IC50 15 nM) and acts as a negative control for Tubacin A, showing anticancer and anti-inflammatory effects.</p>Fórmula:C21H23N3O2Pureza:98%Cor e Forma:SolidPeso molecular:349.43Bryostatin 3
CAS:<p>Bryostatin 3 is a protein kinase C activator.</p>Fórmula:C46H64O17Pureza:98%Cor e Forma:SolidPeso molecular:888.99MSC2504877
CAS:<p>MSC2504877 inhibits tankyrase, boosts CDK4/6 inhibitors, blocks Cyclin D2/E2 upregulation, and strengthens phospho-Rb suppression.</p>Fórmula:C17H18N2O2Pureza:99.72%Cor e Forma:SoildPeso molecular:282.34pan-BET/BD2-IN-1
<p>Pan-BET/BD2-IN-1 (compound 6b) is a selective BET protein inhibitor with BRDT-1Ki of 1.05 μM and BRD4-1Ki of 0.68 μM. It effectively inhibits the growth of MM.1S cancer cells with an IC50 value of 2.6 μM.</p>Cor e Forma:Odour SolidPOI ligand 1
<p>POI ligand 1 serves as a template for the non-selective HDAC inhibitor Vorinostat. It functions as a target protein ligand (PROTAC target protein ligand) in the creation of PROTAC HDAC degraders with anti-tumor properties. Additionally, POI ligand 1 is utilized in the synthesis of FF2049.</p>Fórmula:C14H21N3O3Cor e Forma:SolidPeso molecular:279.335SJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SCor e Forma:SolidPeso molecular:873.94BRD4 degrader AT1
CAS:<p>BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.</p>Fórmula:C48H58ClN9O5S3Pureza:98%Cor e Forma:SolidPeso molecular:972.68Malantide
CAS:<p>Malantide, a synthetic dodecapeptide, boosts and measures PKA activity by undergoing PKA-induced phosphorylation.</p>Fórmula:C72H124N22O21Pureza:98%Cor e Forma:SolidPeso molecular:1633.89mTOR/HDAC-IN-1
CAS:<p>mTOR/HDAC-IN-1, a dual inhibitor for mTOR & HDAC1 with IC50s 0.49 & 0.91 nM, potential anti-cancer agent.</p>Fórmula:C23H23N11O3Cor e Forma:SolidPeso molecular:501.5AS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Fórmula:C18H19N5OCor e Forma:SolidPeso molecular:321.387-Hydroxyneolamellarin A
CAS:<p>7-Hydroxyneolamellarin A, from Dendrilla nigra, inhibits HIF-1α and VEGF in cancer research.</p>Fórmula:C24H19NO5Cor e Forma:SolidPeso molecular:401.41Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH
CAS:<p>Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b), an EZH2 degrader, is employed in lymphoma research [1].</p>Fórmula:C34H43N3O7Cor e Forma:SolidPeso molecular:605.72CPI-1328
CAS:<p>CPI-1328 is an EZH2 inhibitor with a K i value of 63 fM.</p>Fórmula:C28H36ClN3O4SCor e Forma:SolidPeso molecular:546.12PROTAC SMARCA2 degrader-19
CAS:<p>PROTAC SMARCA2 degrader-19 (Compound 46) acts as a degrader of SMARCA2, demonstrating degradation capabilities in A549 and MV411 cells with a DC50 of less than 100 nM. Additionally, this compound degrades SMARCA4 in MV411 cells, but with a significantly higher DC50 of over 1000 nM.</p>Fórmula:C50H58N10O5SCor e Forma:SolidPeso molecular:911.13Bisindolylmaleimide XI hydrochloride
CAS:<p>Bisindolylmaleimide XI hydrochloride is an orally active PKC inhibitor with inhibitory effects on PKCα, PKCβI, PKCβII, and PKCγ (IC50s of 9 nM, 28 nM, 31 nM, 37</p>Fórmula:C28H29ClN4O2Cor e Forma:SolidPeso molecular:489.01Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77Kiss2 peptide acetate
<p>Kiss2 peptide acetate is the acetate form of Kiss2 peptide, serving as a positive regulator of reproduction. It binds to its homologous receptor Kiss2R (GPR54) in COS-7 cells, activating the PKA and PKC signaling pathways through Gas and Gaq proteins. This activation enhances the activity of both cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc).</p>Fórmula:C63H84N16O12·xC2H4O2Cor e Forma:SolidPeso molecular:1257.44 (free base)TB22
<p>TB22 is a non-nucleoside inhibitor of DOT1LR231Q with anticancer activity. It inhibits the malignant phenotype of lung cancer cells harboring the R231Q mutation via the MAPK/ERK signaling pathway, making it useful for lung cancer research.</p>Cor e Forma:Odour SolidZIP
CAS:<p>Novel inhibitor for PKMζ, halts synaptic potentiation and reverses LTP with IC50 of 1-2.5 μM, erasing spatial memory.</p>Fórmula:C90H154N30O17Pureza:98%Cor e Forma:SolidPeso molecular:1928.4UNC10142
<p>UNC10142 (Compound 44) is a small-molecule antagonist of CHD1, with a binding IC50 value of 1.7 μM. It induces a dose-dependent reduction in the viability of PTEN-deficient prostate cancer cells.</p>Fórmula:C33H52N6O3Cor e Forma:SolidPeso molecular:580.8SAH-EZH2
CAS:<p>EZH2/EPP inhibitor, Kd 320 nM. Reduces EZH2, H3K27me3; halts MLL-AF9 leukemia growth; drives monocyte-macrophage differentiation.</p>Fórmula:C155H256N48O40Pureza:98%Cor e Forma:SolidPeso molecular:3432.05PROTAC SMARCA2/4-degrader-26
<p>PROTAC SMARCA2/4-degrader-26 is a PROTAC targeting the SMARCA2/4 proteins. It is composed of the ligand for PROTAC targeting proteins, 2-(4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)acetic acid, an E3 ligase component (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, and a PROTAC linker (S)-2-Amino-3,3-dimethylbutanoic acid. The coupled complex of the E3 ubiquitin ligase ligand + Linker is referred to as (S,R,S)-AHPC.</p>Fórmula:C38H47N9O5SCor e Forma:SolidPeso molecular:741.9GSK232
CAS:<p>GSK232 is a highly selective and cellularly penetrant inhibitor of CECR2 with outstanding physicochemical properties.</p>Fórmula:C21H27ClN6O3SCor e Forma:SolidPeso molecular:479.0(S,R,S)-AHPC-C5-COOH
CAS:<p>E3 ligase ligand-linker '(S,R,S)-AHPC-C5-COOH' for PROTACs, VH032 inhibits VHL/HIF-1α with 185 nM Kd, may aid anemia and ischemic disease research.</p>Fórmula:C29H42N4O5SPureza:98%Cor e Forma:SolidPeso molecular:558.73PROTAC SMARCA2/4-degrader-27
CAS:<p>PROTAC SMARCA2/4-degrader-27 (PROTAC 2) serves as a targeted degrader, utilizing PROTAC technology to degrade both SMARCA2 and SMARCA4.</p>Fórmula:C49H58FN9O6SCor e Forma:SolidPeso molecular:920.11Kiss2 peptide
CAS:<p>Kiss2 peptide functions as a positive regulator of reproductive behavior. In COS-7 cells, it binds to its homologous G-protein coupled receptor Kiss2R (GPR54), activating the PKA and PKC signaling pathways through Gas and Gaq proteins. This enhances the activity of cAMP response element-dependent luciferase (CRE-luc) and serum response element-dependent luciferase (SRE-luc).</p>Fórmula:C63H84N16O12Peso molecular:1257.44PAD2-IN-1
CAS:<p>PAD2-IN-1 is a selective benzimidazole-derived inhibitor with a 95-fold and 79-fold higher affinity for PAD2 over PAD4 and PAD3, respectively.</p>Fórmula:C25H29FN6O3Cor e Forma:SolidPeso molecular:480.544FHD-286
CAS:<p>FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.</p>Fórmula:C24H30N6O6S2Pureza:99.73%Cor e Forma:SolidPeso molecular:562.66SIRT1/2/3-IN-1
CAS:<p>Potent SIRT1/2/3-IN-1 inhibits SIRT1/2/3 with IC50: 0.54, 0.25, 0.72 μM; used in cancer research.</p>Fórmula:C46H63N9O8S2Cor e Forma:SolidPeso molecular:934.18NF-κB/HIF-1α-IN-1
<p>NF-κB/HIF-1α-IN-1 (compound 9c) effectively inhibits the NF-κB activation pathway and demonstrates selective antifibrotic activity. This compound exhibits no significant cytotoxicity in NCI tumor cell lines. In rat models, NF-κB/HIF-1α-IN-1 successfully ameliorates liver fibrosis, suppresses the expression levels of NF-κB and HIF-1α, and induces Nrf2.</p>Fórmula:C24H27N7O4Cor e Forma:SolidPeso molecular:477.21245MZP-55
CAS:<p>MZP-55 is a selective BRD3/4 degrader based on PROTAC technology(Brd4BD2 with Kd of 8 nM)</p>Fórmula:C57H70ClN7O10SPureza:98%Cor e Forma:SolidPeso molecular:1080.73PROTAC BRD4 Degrader-15
CAS:<p>PROTAC BRD4 Degrader-15 targets von Hippel-Lindau and BRD4 with IC50s 7.2/8.1 nM and degrades BRD4 in cancer cells.</p>Fórmula:C57H62F2N10O10S2Cor e Forma:SolidPeso molecular:1149.3PROTAC BRD4 Degrader-20
CAS:<p>PROTAC BRD4 Degrader-20 (compound 195) is a bifunctional degrader of BRD4 [1].</p>Fórmula:C55H58ClN9O7S2Cor e Forma:SolidPeso molecular:1056.69AURKA against 1
<p>Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.</p>Fórmula:C28H32FN9O2Cor e Forma:SolidPeso molecular:545.61MS2133
<p>MS2133 is a DOT1L PROTAC degrader. It facilitates the ubiquitination and degradation of DOT1L in THP-1 and MV4-11 cells, with DC50 values of 56 nM and 25 nM, respectively, and reduces H3K79 methylation. MS2133 also inhibits the growth of MLL-r leukemia cells, demonstrating anticancer activity.</p>Fórmula:C58H66ClF3N14O11S2Cor e Forma:SolidPeso molecular:1290.41175OKI-006
CAS:<p>OKI-006 is an oral HDAC inhibitor with potential for cancer research, derived from largazole.</p>Fórmula:C21H30N4O5S2Cor e Forma:SolidPeso molecular:482.62HSP90/LSD1-IN-1
<p>HSP90/LSD1-IN-1 (compound 6) is a dual inhibitor of HSP90 and LSD1. This compound effectively inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI50 values of 0.24 μM and 0.30 μM, respectively.</p>Cor e Forma:Odour SolidZifcasiran
CAS:<p>Zifcasiran reduces HIF synthesis, has antitumor properties, useful in renal carcinoma studies.</p>Fórmula:C737H972F20N211O349P43S8Cor e Forma:SolidPeso molecular:20339.13Tanshinol borneol ester
CAS:<p>Tanshinol borneol ester stimulates angiogenesis via Akt/MAPK pathways and has anti-ischemic, anti-atherosclerosis effects.</p>Fórmula:C19H26O5Cor e Forma:SolidPeso molecular:334.41BB-Cl-Amidine TFA
<p>BB-Cl-Amidine (TFA) is an inhibitor of peptidylarginine deiminase (PAD).</p>Cor e Forma:Odour SolidPROTAC SMARCA2 degrader-23
CAS:<p>PROTAC SMARCA2 degrader-23 (Example 1) is an effective and selective degrader of PROTAC SMARCA2, with a DC50 value of less than 100 nM. It has potential for use in cancer research.</p>Fórmula:C47H57N9O6SCor e Forma:SolidPeso molecular:876.08TAS-119
CAS:<p>TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95</p>Fórmula:C23H22Cl2FN5O3Pureza:99.65%Cor e Forma:SolidPeso molecular:506.36KDM4 ligand-1
<p>KDM4ligand-1 is a ligand targeting the protein (histone lysine demethylase KDM4) in PROTACs. It can be utilized for the synthesis of PROTACs.</p>Cor e Forma:Odour SolidDihydrochlamydocin analog-1
CAS:<p>Dihydrochlamydocinanalog-1 (compound 2) is a Chlamydocin analog that inhibits the deacetylation of histone H4 peptides, with an IC50 of 30 nM.</p>Fórmula:C28H40N4O6Cor e Forma:SolidPeso molecular:528.64dBET23
CAS:<p>dBET23 is a BRD4 degrader.</p>Fórmula:C43H45ClN8O9SCor e Forma:SolidPeso molecular:885.38LH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Fórmula:C29H31F3N6O2SCor e Forma:SolidPeso molecular:584.66KAT6-IN-2
<p>KAT6-IN-2 is a potent inhibitor of KAT6, showing promise for use in cancer research.</p>Cor e Forma:Odour SolidPRMT1-IN-1
CAS:<p>PRMT1-IN-1 is a PRMT1 inhibitor.</p>Fórmula:C20H7Br6NO5Cor e Forma:SolidPeso molecular:820.702Nicotinamide riboside tartrate
CAS:<p>NRT is an oral NAD+ precursor, boosts NAD+, activates SIRT1/3, provides vitamin B3, enhances metabolism, and may mitigate Alzheimer's.</p>Fórmula:C15H20N2O11Cor e Forma:SolidPeso molecular:404.33CD532 hydrochloride
<p>CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.</p>Cor e Forma:SolidACBI2
CAS:<p>ACBI2: potent, oral VHL PROTAC, EC50=7nM; degrades SMARCA2, DC50=1nM in RKO cells; for lung cancer research.</p>Fórmula:C56H68BrFN8O5SCor e Forma:SolidPeso molecular:1064.16PROTAC SMARCA2/4-degrader-30
CAS:<p>Compound I-291, also known as PROTAC SMARCA2/4-degrader-30, targets the catalytic subunits of the SWI/SNF complex, specifically SMARCA2 and SMARCA4. It effectively degrades SMARCA2 in A549 and MV411 cells, as well as SMARCA4 in MV411 cells, with a degradation concentration (DC50) of less than 100 nM.</p>Fórmula:C44H51N11O4Cor e Forma:SolidPeso molecular:797.95EP300/CBP ligand 2
<p>EP300/CBP ligand 2 (compound S19) serves as a specific ligand for the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). It plays a critical role in PROTAC technology by acting as a target protein ligand. By linking to an E3 ubiquitin ligase ligand via the PROTAC Linker, it facilitates the synthesis of PROTAC molecules capable of targeted protein degradation. For instance, when EP300/CBP ligand 2 is connected to the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc, it results in the formation of the PROTAC molecule dCE-2.</p>Fórmula:C20H18N6OCor e Forma:SolidPeso molecular:358.4HD-TAC7
<p>HD-TAC7 is a PROTAC HDAC degrader; IC50s: HDAC1 (3.6μM), HDAC2 (4.2μM), HDAC3 (1.1μM); reduces NF-κB p65; researched for asthma, COPD.</p>Fórmula:C33H32FN7O7Cor e Forma:SolidPeso molecular:657.65HIF-1 inhibitor-5
<p>HIF-1 inhibitor-5 (Compound 16e) is a potent inhibitor of HIF-1, exhibiting an IC50 value of 2.38 μM and demonstrating significant anti-angiogenic potential [1</p>Fórmula:C28H35NO5Cor e Forma:SolidPeso molecular:465.58HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SCor e Forma:SolidPeso molecular:1236.36Go6976
CAS:<p>Go6976 is a PKC inhibitor, widely used in research to probe PKC functions in health and disease.</p>Fórmula:C24H18N4OPureza:95.89%Cor e Forma:Off-White To Yellow SolidPeso molecular:378.43GSK 591 dihydrochloride
CAS:<p>Strong PRMT5 inhibitor with 4 nM IC50, surpassing other PRMTs; halts MCL growth in lab tests.</p>Fórmula:C22H30Cl2N4O2Cor e Forma:SolidPeso molecular:453.41HIF-PHD-IN-4
<p>HIF-PHD-IN-4 (Compound 13) is an orally active PHD2 inhibitor with an IC50 of 100 nM. At a dose of 2 mg/kg, it effectively enhances G-CSF-induced mobilization of hematopoietic stem cells in mice. HIF-PHD-IN-4 is suitable for research in the oncology field.</p>Cor e Forma:Odour SolidINCB059872
CAS:<p>INCB059872: potent, oral, selective LSD1 inhibitor for myeloid leukemia research.</p>Fórmula:C23H34N2O3Cor e Forma:SolidPeso molecular:386.536Protein Kinase C (19-36)
CAS:<p>Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (PKC), with an IC50 of 0.18 μM.</p>Fórmula:C93H159N35O24Pureza:98%Cor e Forma:SolidPeso molecular:2151.48PIM-IN-1
CAS:<p>PIM-IN-1 is a pan-PIM kinase inhibitor (KG-1, EC 50 = 61 nM; pS6, EC 50 = 71 nM).</p>Fórmula:C15H18ClFN4OCor e Forma:SolidPeso molecular:324.78KDM5-C49 hydrochloride
<p>KDM5-C49 hydrochloride selectively inhibits KDM5A/B/C demethylases (IC50: 40/160/100 nM) for cancer research.</p>Fórmula:C15H25ClN4O3Cor e Forma:SolidPeso molecular:344.84JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OCor e Forma:SolidPeso molecular:407.401PROTAC BRD4 Degrader-1
CAS:<p>PROTAC BRD4 Degrader-1 is an efficacious degrader of BRD4(BRD4 BD1,IC50 of 41.8 nM).</p>Fórmula:C40H37N9O8Pureza:98%Cor e Forma:SolidPeso molecular:771.78FTX-6058 hydrochloride
CAS:<p>FTX-6058 hydrochloride is a potent EED inhibitor, induces HbF, and aids sickle cell and β-thalassemia research.</p>Fórmula:C22H19ClFN5O2Cor e Forma:SolidPeso molecular:439.87HDAC6-IN-42
<p>HDAC6-IN-42 (compound 2b) is an HDAC6 inhibitor with an IC50 of 0.009 μM, demonstrating significant anti-leukemia activity and synergistic effects with Decitabine, indicating its potential use in the research of Acute Myeloid Leukemia (AML).</p>Fórmula:C24H28FN3O4Peso molecular:441.20638PROTAC_ERRα
CAS:<p>PROTAC_ERRα is a potent, selective degrader of ERRα, efficiently facilitating its proteasomal degradation.</p>Fórmula:C46H47F3N6O9S2Cor e Forma:SolidPeso molecular:949.03SMARCA2 degrader-17
CAS:<p>SMARCA2 degrader-17 is a degrader of SMARCA2, exhibiting synergistic antiproliferative effects with Adagrasib in cancer cells and capable of inhibiting tumor growth.</p>Fórmula:C47H58N10O6SCor e Forma:SolidPeso molecular:891.09C 21
CAS:<p>PRMT1 inhibitor, IC50=1.8μM; 5x more selective than PRMT6; >250x over PRMT3, CARM1.</p>Fórmula:C90H161ClN36O24Pureza:98%Cor e Forma:SolidPeso molecular:2166.94mUNO
CAS:<p>mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to murine CD206, targeting tumor-associated macrophages that express CD206/MRC1. Additionally, mUNO can interact with human recombinant CD206.</p>Fórmula:C22H39N7O8SCor e Forma:SolidPeso molecular:561.652Y16526
<p>Y16526 is a potent inhibitor of the CBP/p300 bromodomain (CBP/p300bromodomain) with an IC50 of 0.03 μM. Y16524 shows potential for research in acute myeloid leukemia (AML).</p>Fórmula:C30H34FN5O4Cor e Forma:SolidPeso molecular:547.62GXH-II-052
<p>GXH-II-052: Potent BET inhibitor, binds BRD4/BRDT (Kd 0.6-28 nM), anti-proliferative, reduces c-Myc expression.</p>Fórmula:C62H76Cl2F2N14O11S2Cor e Forma:SolidPeso molecular:1366.39TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Cor e Forma:SolidPeso molecular:404.16485Sirt2-IN-7
<p>Sirt2-IN-7, a selective SIRT2 inhibitor, has IC50 and Ki values of 178.2 nM and 154.3 nM, useful in cancer research.</p>Fórmula:C22H38Cl2K3N3OSCor e Forma:SolidPeso molecular:831.98PROTAC PARP1 degrader-4
<p>PROTAC PARP1 degrader-4 (Compound 180055) is a selective PARP1 PROTAC degrader, demonstrating DC50 values of 180 nM and 240 nM in T47D and MDA-MB-231 cell lines, respectively. It facilitates the ubiquitination and degradation of PARP1 and inhibits its enzymatic activity without causing significant DNA trapping effects. Additionally, PROTAC PARP1 degrader-4 can inhibit tumors with BRCA gene mutations while having minimal impact on the growth of normal cells.</p>Fórmula:C51H62FN7O6SCor e Forma:SolidPeso molecular:920.145WWL0245
CAS:<p>WWL0245 is a potent and selective BRD4-targeting PROTAC that exhibits sub-nanomolar degradation efficiency (DC50 < 1 nM) for BRD4 over BRD2/3 and PLK1 (DC50 > 1</p>Fórmula:C45H51N11O8Pureza:98%Cor e Forma:SolidPeso molecular:873.96PRMT5-IN-11
CAS:<p>PRMT5-IN-11 demonstrates potent structure-dependent inhibition against the protein methyltransferase PRMT5:MEP50 complex at submicromolar concentrations.</p>Fórmula:C13H17N5O4Cor e Forma:SolidPeso molecular:307.31Foenumoside B
CAS:<p>Foenumoside B, a triterpene saponin extracted from Lysimachia foenum-graecum, stimulates AMPK signaling, suppresses PPARγ-induced adipogenesis, and promotes</p>Fórmula:C60H96O25Pureza:98%Cor e Forma:SolidPeso molecular:1217.39BBDDL2204
<p>BBDDL2204 (compound 13) is a potent and selective covalent inhibitor of EZH2, demonstrating an IC50 of 2.5 nM against EZH2Y641F.</p>Fórmula:C37H47N5O5SCor e Forma:SolidPeso molecular:673.32979MAT2A-IN-11
<p>MAT2A Allosteric Inhibitor 1, also known as Compound 5, is a selective inhibitor of methionine adenosyltransferase (MAT) demonstrating potent activity with an</p>Fórmula:C21H22N6OPureza:98%Cor e Forma:SolidPeso molecular:374.44JMJD6 inhibitor WL12
CAS:<p>WL12 (ZINC6733033): First-in-class JMJD6 inhibitor; halts JMJD6-dependent cervical/liver cancer cell growth.</p>Fórmula:C16H11N3O2Pureza:98.57%Cor e Forma:SolidPeso molecular:277.28BRD9 Degrader-1
<p>BRD9 Degrader-1 functions as a BRD9 degrader, demonstrating micromolar binding affinity towards BRD9 and nanomolar affinity for the ternary complex involving</p>Pureza:98%Cor e Forma:Odour SolidIzilendustat
CAS:<p>Tert-butyl compound inhibits human EGLN-1; confirmed by spectrometry after 20 mins.</p>Fórmula:C22H28ClN3O4Pureza:99.95%Cor e Forma:SolidPeso molecular:433.93NPC-15437 dihydrochloride
CAS:<p>NPC-15437 dihydrochloride is a PKC inhibitor blocking enzyme activity and phorbol ester binding, selective over other kinases, in cellular signaling research.</p>Fórmula:C25H52Cl2N4O2Cor e Forma:SolidPeso molecular:511.62TO-1187
<p>TO-1187 is a selective HDAC6 PROTAC degrader with a DC50 of 5.81 nM. It enhances the ubiquitination and subsequent degradation of HDAC6, making it useful for research in hematological malignancies and solid tumors.</p>Cor e Forma:Odour SolidBET-IN-17
<p>BET-IN-17, also known as compound 16, serves as a pan-inhibitor for BET, exhibiting inhibitory potencies (pIC50) of 7.8 for BET BD1 and 7.6 for BET BD2 [1].</p>Fórmula:C30H36N4O2Pureza:98%Cor e Forma:SolidPeso molecular:484.63CARM1 degrader-2
<p>PROTAC CARM1 degrader-2 (compound 3e), with a DC50 value of 8.8 nM, is a VHL- and proteasome-dependent degrader of co-activator associated</p>Fórmula:C72H100N12O7SPureza:98%Cor e Forma:SolidPeso molecular:1277.71MC4171
<p>MC4171 is a selective KAT8 inhibitor with antiproliferative activity and can be used to study cancer.</p>Fórmula:C21H15N3O3Pureza:99.56%Cor e Forma:SolidPeso molecular:357.36TH1834
CAS:<p>TH1834 is a specific inhibitor of Tip60/KAT5 histone acetyltransferase. TH1834 induces apoptosis and DNA damage in MCF.</p>Fórmula:C33H40N6O3Pureza:99.96%Cor e Forma:SolidPeso molecular:568.71DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Fórmula:C26H35N7O5Cor e Forma:SolidPeso molecular:525.6GSK2879552
CAS:<p>GSK2879552: oral, irreversible LSD1 inhibitor with potential cancer-fighting properties.</p>Fórmula:C23H28N2O2Pureza:99.22%Cor e Forma:SolidPeso molecular:364.48GSK-J2
CAS:<p>GSK-J2 is an inactive enantiomer of GSK-J1 that is lipophilic and serves as an inactive control for GSK-J21.</p>Fórmula:C22H23N5O2Pureza:97.55%Cor e Forma:SolidPeso molecular:389.45AZ505 ditrifluoroacetate
CAS:<p>AZ505 ditrifluoroacetate is an effective and selective SMYD2 inhibitor (IC50: 0.12 μM).</p>Fórmula:C33H40Cl2F6N4O8Cor e Forma:SolidPeso molecular:805.59
